BofA/Merrill Lynch downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Neutral.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $91.11 yesterday.